Pharma wins permanent price shield on orphan drugs under Medicare

What it does

This bill expands the orphan drug exemption from Medicare's drug price negotiation program. It allows drugs that were once designated as orphan drugs (for rare diseases) to retain their exemption even after they are approved for broader uses, and it clarifies that orphan drugs treating multiple rare diseases qualify for the exemption. The primary beneficiaries are pharmaceutical manufacturers of orphan drugs, who gain protection from price negotiation on these medications.

Why we flagged it

The bill's operative mechanism is to expand and clarify exemptions from Medicare's drug price negotiation authority, shielding a class of drugs from price controls. This is a direct carve-out for pharmaceutical manufacturers, not a public health measure.

What the text implies

• Drugs approved for rare diseases can now retain orphan exemption indefinitely even after gaining approval for common conditions, potentially allowing manufacturers to avoid price negotiation on blockbuster drugs that originated as orphan designations.
• The expansion to 'one or more rare diseases' (plural) may capture drugs treating multiple rare indications simultaneously, broadening the exemption beyond the original intent of protecting single-indication orphan drugs.
• The bill does not define a time limit or sunset for the exemption, meaning a drug could theoretically retain orphan status protection in perpetuity if it maintains any rare disease indication.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients and Medicare beneficiaries lose negotiating leverage on a broader class of drugs. By exempting drugs that were once orphan-designated even after they gain broader market approvals, and by including drugs treating multiple rare diseases, the bill protects manufacturer pricing power at the expense of public payers and patients who depend on Medicare coverage.

Who stands to gain

• pharmaceutical manufacturers with orphan drug portfolios
• biotech companies developing rare disease treatments

Named in the bill

Social Security Act, Medicare, Drug Price Negotiation Program, orphan drugs, Federal Food, Drug, and Cosmetic Act, Section 526, rare diseases

Where it stands

1 cosponsor: 1 Democrats.

• May 22, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• May 22, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance. (text: CR S3119)”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

16 lobbying clients named this bill on 24 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $7,890,000 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 95% of bills with at least one filing.

John Barrasso, the sponsor, reported $408,500 in PAC receipts in the 2026 cycle.

• Astrazeneca Pharmaceuticals Lp — $2,350,000 on 2 filings
• Acadia Pharmaceuticals — $1,290,000 on 2 filings
• Incyte Corporation — $1,280,000 on 2 filings
• Boehringer Ingelheim USA Corporation — $710,000 on 1 filing
• Emd Serono Inc — $700,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.